EA201791770A1 - Фармацевтические композиции для комбинированной терапии - Google Patents
Фармацевтические композиции для комбинированной терапииInfo
- Publication number
- EA201791770A1 EA201791770A1 EA201791770A EA201791770A EA201791770A1 EA 201791770 A1 EA201791770 A1 EA 201791770A1 EA 201791770 A EA201791770 A EA 201791770A EA 201791770 A EA201791770 A EA 201791770A EA 201791770 A1 EA201791770 A1 EA 201791770A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- combination
- agonist
- present
- fxr
- delta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к фармацевтической композиции, содержащей комбинацию агониста FXR и по меньшей мере одного гиполипидемического средства (например, агониста PPAR-альфа, агониста PPAR-дельта, двойного агониста PPAR-альфа и дельта и/или статина). Также раскрывается применение комбинации для лечения или предупреждения заболевания или состояния, опосредованного FXR, такого как первичный билиарный цирроз (РВС), первичный склерозирующий холангит (PSC), портальная гипертензия, хологенная диарея, NAFLD (неалкогольная жировая болезнь печени), NASH (стеатогепатит, не индуцированный алкоголем) и другие хронические заболевания печени. Комбинация согласно настоящему изобретению является применимой для лечения или предупреждения состояний, связанных с повышенными уровнями липидов и ферментов печени. Настоящее изобретение также относится к упаковкам или наборам, содержащим фармацевтическую комбинацию.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562113134P | 2015-02-06 | 2015-02-06 | |
PCT/US2016/016694 WO2016127019A2 (en) | 2015-02-06 | 2016-02-05 | Pharmaceutical compositions for combination therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791770A1 true EA201791770A1 (ru) | 2017-12-29 |
EA036404B1 EA036404B1 (ru) | 2020-11-06 |
Family
ID=56564878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791770A EA036404B1 (ru) | 2015-02-06 | 2016-02-05 | Фармацевтические композиции для комбинированной терапии |
Country Status (31)
Country | Link |
---|---|
US (3) | US11311557B2 (ru) |
EP (2) | EP4035665A1 (ru) |
JP (2) | JP7306791B2 (ru) |
KR (1) | KR20170115071A (ru) |
CN (1) | CN107405325B (ru) |
AR (1) | AR103624A1 (ru) |
AU (2) | AU2016215179B2 (ru) |
BR (1) | BR112017016766B1 (ru) |
CA (1) | CA2976056C (ru) |
CL (3) | CL2017001983A1 (ru) |
CO (1) | CO2017007959A2 (ru) |
CR (1) | CR20170356A (ru) |
DK (1) | DK3253382T3 (ru) |
EA (1) | EA036404B1 (ru) |
EC (1) | ECSP17057848A (ru) |
ES (1) | ES2905872T3 (ru) |
GT (1) | GT201700174A (ru) |
HK (1) | HK1246191A1 (ru) |
IL (2) | IL253719B (ru) |
MA (1) | MA40814A1 (ru) |
MX (1) | MX2017010131A (ru) |
NI (1) | NI201700100A (ru) |
PE (1) | PE20180027A1 (ru) |
PH (1) | PH12017501384A1 (ru) |
SG (1) | SG11201706347SA (ru) |
SV (1) | SV2017005512A (ru) |
TN (1) | TN2017000344A1 (ru) |
TW (1) | TW201628625A (ru) |
UA (1) | UA125744C2 (ru) |
WO (1) | WO2016127019A2 (ru) |
ZA (1) | ZA201706007B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3253382T3 (da) | 2015-02-06 | 2022-02-14 | Intercept Pharmaceuticals Inc | Farmaceutiske sammensætninger til kombinationsterapi |
EP3280421B1 (en) * | 2015-04-07 | 2023-12-27 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
MX2018003649A (es) * | 2015-09-24 | 2018-05-11 | Intercept Pharmaceuticals Inc | Metodos e intermedios para la preparacion de derivados de acido biliar. |
US20220133666A1 (en) | 2016-03-31 | 2022-05-05 | Genfit | Methods of treatment of cholestatic diseases |
US11331292B2 (en) | 2016-03-31 | 2022-05-17 | Genfit | Methods of treatment of cholestatic diseases |
MX2021015783A (es) * | 2016-03-31 | 2022-12-09 | Genfit | Metodos de tratamiento de enfermedades colestaticas. |
BR112019011740A2 (pt) | 2016-12-09 | 2019-10-29 | Cadila Healthcare Ltd | composição farmacêutica e método para o tratamento de colangite biliar primária |
JP2020508316A (ja) * | 2017-02-21 | 2020-03-19 | ジェンフィGenfit | Pparアゴニストとfxrアゴニストとの組合せ |
US20190076500A1 (en) * | 2017-09-13 | 2019-03-14 | Novartis Ag | Combinations comprising fxr agonists |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
WO2020208205A1 (en) * | 2019-04-10 | 2020-10-15 | Genfit | Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists |
JP2022536060A (ja) * | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 胆汁鬱滞性肝疾患の処置で使用するためのfxrアゴニストおよびフィブラートを含む医薬組成物 |
CN110287493B (zh) * | 2019-06-28 | 2023-04-18 | 中国科学技术信息研究所 | 风险短语识别方法、装置、电子设备及存储介质 |
JP2022540699A (ja) * | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
EP4031124A4 (en) * | 2019-09-20 | 2024-01-24 | Reneo Pharmaceuticals Inc | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF DEE DISEASE |
EP4061357A4 (en) * | 2019-11-22 | 2024-01-10 | Avolynt | USE OF SGLT2 INHIBITORS TO TREAT PRIMARY BILIARY CHOLANGITIS |
CN111690731B (zh) * | 2020-05-22 | 2021-09-28 | 河南大学 | Fxr激动剂在治疗肝性脑病中的应用 |
CN112885471B (zh) * | 2021-03-12 | 2023-01-24 | 上海中医药大学附属岳阳中西医结合医院 | 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统 |
WO2023147141A1 (en) * | 2022-01-28 | 2023-08-03 | Intercept Pharmaceuticals, Inc. | Combination therapy |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB860303A (en) | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
US3262580A (en) | 1964-06-23 | 1966-07-26 | Mcdowell Wellman Eng Co | Slewable gantry crane |
FR1498459A (ru) | 1965-07-30 | 1968-01-08 | ||
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4058552A (en) | 1969-01-31 | 1977-11-15 | Orchimed Sa | Esters of p-carbonylphenoxy-isobutyric acids |
FI52570C (fi) | 1969-04-16 | 1977-10-10 | Sumitomo Chemical Co | Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi. |
AT296986B (de) | 1969-08-13 | 1972-03-10 | Merz & Co | Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen |
DE2230383C3 (de) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
JPS5118954B2 (ru) | 1972-02-04 | 1976-06-14 | ||
US3948973A (en) | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
DE2308826C3 (de) | 1973-02-22 | 1980-03-27 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel |
FR2244511B1 (ru) | 1973-07-05 | 1977-07-15 | Roussel Uclaf | |
ES8101585A1 (es) | 1980-02-15 | 1980-12-16 | Especialidades Farmaco Terape | Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
EP0607536B1 (en) | 1992-12-08 | 2001-01-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivatives |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
BR9806989A (pt) * | 1997-01-24 | 2000-03-14 | Univ California | Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero. |
IL133957A0 (en) * | 1997-08-29 | 2001-04-30 | Pfizer Prod Inc | Combination therapy comprising amlodipine and a statin compound |
CA2307820C (en) | 1997-10-27 | 2007-04-24 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US20030109467A1 (en) | 2001-11-15 | 2003-06-12 | Isis Pharmaceuticals Inc. | Antisense modulation of human FXR expression |
EP1140036A2 (en) | 1998-12-18 | 2001-10-10 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
DE69940958D1 (de) | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
AU2409600A (en) | 1999-01-07 | 2000-07-24 | Tularik Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
US6071955A (en) * | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
PL357674A1 (en) | 2000-04-19 | 2004-07-26 | Thomas Julius Borody | Compositions and therapies for hyperlipidaemia-associated disorders |
AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
EP1318976B1 (en) | 2000-09-18 | 2004-11-24 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
US7259186B2 (en) | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
GB0405349D0 (en) * | 2004-03-10 | 2004-04-21 | Univ Birmingham | Cancer therapy and medicaments therefor |
HUE032928T2 (hu) | 2004-03-12 | 2017-11-28 | Intercept Pharmaceuticals Inc | Fibrózis kezelése FXR-ligandumok alkalmazásával |
PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
US20060252670A1 (en) | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
WO2006121861A2 (en) | 2005-05-05 | 2006-11-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
JP2010517931A (ja) | 2006-02-14 | 2010-05-27 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Fxr媒介性の疾患または状態の予防または治療用のfxrリガンドとしての胆汁酸誘導体 |
US20070197606A1 (en) | 2006-02-22 | 2007-08-23 | Burczynski Frank J | Use of ppar agonists as anti-oxidants |
CA2679608A1 (en) * | 2006-03-22 | 2007-10-04 | President And Fellows Of Harvard College | Methods and compositions for treating hypercholesterolemia and atherosclerosis |
EP2029547B1 (en) | 2006-05-24 | 2010-04-28 | Eli Lilly And Company | Fxr agonists |
CA2651373A1 (en) | 2006-05-24 | 2007-12-06 | Eli Lilly And Company | Compounds and methods for modulating fxr |
CA2656320C (en) * | 2006-06-27 | 2015-04-28 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
BRPI0621942A2 (pt) | 2006-08-04 | 2011-10-18 | Aska Pharm Co Ltd | preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
WO2008039829A2 (en) | 2006-09-26 | 2008-04-03 | Ironwood Pharmaceuticals, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
US20080300235A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
US20080299118A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
US20090215748A1 (en) | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
ES2681794T3 (es) * | 2009-11-26 | 2018-09-17 | Genfit | Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
DK3336097T3 (da) | 2012-06-19 | 2020-09-28 | Intercept Pharmaceuticals Inc | Fremstilling af ikke-krystallinsk obeticholsyre |
NZ745013A (en) | 2012-10-26 | 2019-08-30 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
PT3360881T (pt) * | 2013-05-14 | 2021-02-19 | Intercept Pharmaceuticals Inc | Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x |
US10077268B2 (en) * | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
DK3253382T3 (da) | 2015-02-06 | 2022-02-14 | Intercept Pharmaceuticals Inc | Farmaceutiske sammensætninger til kombinationsterapi |
-
2016
- 2016-02-05 DK DK16747312.3T patent/DK3253382T3/da active
- 2016-02-05 TN TNP/2017/000344A patent/TN2017000344A1/en unknown
- 2016-02-05 BR BR112017016766-2A patent/BR112017016766B1/pt active IP Right Grant
- 2016-02-05 ES ES16747312T patent/ES2905872T3/es active Active
- 2016-02-05 EP EP21208443.8A patent/EP4035665A1/en active Pending
- 2016-02-05 CA CA2976056A patent/CA2976056C/en active Active
- 2016-02-05 AR ARP160100332A patent/AR103624A1/es unknown
- 2016-02-05 CR CR20170356A patent/CR20170356A/es unknown
- 2016-02-05 WO PCT/US2016/016694 patent/WO2016127019A2/en active Application Filing
- 2016-02-05 PE PE2017001322A patent/PE20180027A1/es unknown
- 2016-02-05 TW TW105104019A patent/TW201628625A/zh unknown
- 2016-02-05 EP EP16747312.3A patent/EP3253382B1/en not_active Revoked
- 2016-02-05 UA UAA201708864A patent/UA125744C2/uk unknown
- 2016-02-05 AU AU2016215179A patent/AU2016215179B2/en active Active
- 2016-02-05 KR KR1020177024607A patent/KR20170115071A/ko not_active Application Discontinuation
- 2016-02-05 SG SG11201706347SA patent/SG11201706347SA/en unknown
- 2016-02-05 US US15/548,537 patent/US11311557B2/en active Active
- 2016-02-05 MA MA40814A patent/MA40814A1/fr unknown
- 2016-02-05 JP JP2017541334A patent/JP7306791B2/ja active Active
- 2016-02-05 CN CN201680015586.6A patent/CN107405325B/zh active Active
- 2016-02-05 MX MX2017010131A patent/MX2017010131A/es unknown
- 2016-02-05 EA EA201791770A patent/EA036404B1/ru unknown
-
2017
- 2017-07-30 IL IL253719A patent/IL253719B/en unknown
- 2017-08-01 PH PH12017501384A patent/PH12017501384A1/en unknown
- 2017-08-03 CL CL2017001983A patent/CL2017001983A1/es unknown
- 2017-08-04 GT GT201700174A patent/GT201700174A/es unknown
- 2017-08-04 NI NI201700100A patent/NI201700100A/es unknown
- 2017-08-04 CO CONC2017/0007959A patent/CO2017007959A2/es unknown
- 2017-08-07 SV SV2017005512A patent/SV2017005512A/es unknown
- 2017-08-31 EC ECIEPI201757848A patent/ECSP17057848A/es unknown
- 2017-09-04 ZA ZA2017/06007A patent/ZA201706007B/en unknown
-
2018
- 2018-04-19 CL CL2018001006A patent/CL2018001006A1/es unknown
- 2018-05-04 HK HK18105766.1A patent/HK1246191A1/zh unknown
- 2018-12-14 CL CL2018003604A patent/CL2018003604A1/es unknown
-
2021
- 2021-02-17 AU AU2021201015A patent/AU2021201015A1/en not_active Abandoned
- 2021-10-11 JP JP2021166629A patent/JP2022000483A/ja not_active Withdrawn
-
2022
- 2022-02-23 IL IL290823A patent/IL290823A/en unknown
- 2022-03-21 US US17/700,317 patent/US20220280533A1/en active Pending
- 2022-03-21 US US17/700,392 patent/US20220280534A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791770A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
BR112018007857A2 (pt) | combinações de gemcabene para o tratamento de doença cardiovascular | |
PH12015502136A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
EA201592020A1 (ru) | Новая композиция для неалкогольной жировой болезни печени (нажбп) | |
EA201691404A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов бромодомена | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
BR112013017635A2 (pt) | inibidores de cyp11b, cyp17 e/ou cyp21 | |
AR105493A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
AU2018246796A1 (en) | S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis | |
BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
MX2021014585A (es) | Composiciones farmaceuticas que comprenden un agonista de fxr y un fibrato para usarse en el tratamiento de la enfermedad hepatica colestatica. | |
PH12016501548B1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
EP3510014A4 (en) | COMPOSITIONS AND METHODS FOR USE OF GAMMA KETOALDEHYD CATCHERS FOR TREATING, PREVENTING OR IMPROVING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD, OR DISEASES | |
CL2019002020A1 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer. | |
BR112022008639A2 (pt) | Tratamento de distúrbios do fígado | |
EA201891739A1 (ru) | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH) | |
BR112022004489A2 (pt) | Composto ou composição para uso | |
BR112018005843A2 (pt) | inibidores de calicreína de plasma humano |